Avicel PH-200 NF, Microcrystalline Cellulose NF, Net Content/Gross Weight 20.0 KG / 21.1 KG bulk ...
FDA Drug Recall #D-0546-2023 — Class III — April 13, 2023
Recall Summary
| Recall Number | D-0546-2023 |
| Classification | Class III — Low risk |
| Date Initiated | April 13, 2023 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | DuPont Nutrition USA, Inc |
| Location | Newark, DE |
| Product Type | Drugs |
| Quantity | 93,660 kg in bulk drums, boxes & sacks |
Product Description
Avicel PH-200 NF, Microcrystalline Cellulose NF, Net Content/Gross Weight 20.0 KG / 21.1 KG bulk container, Manufactured by: DuPont Nutrition USA, Inc., 1301 Ogletown Road, Newark, DE 19711, USA; Manufactured in USA; Headquarters: DuPont Nutrition Biosciences ApS, Langebrogade 1, Copenhagen, Denmark.
Reason for Recall
Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Distribution Pattern
Nationwide in the USA, Malta, Canada, China, Peru, Mexico, Australia, Saudi Arabia, Spain, Dominican Republic, Puerto Rico, Singapore, Bangkok, Ireland, India, and Columbia.
Lot / Code Information
Batch Numbers: 2173766945, 2173768895, PN20834306, 217373201, PN20834301
Other Recalls from DuPont Nutrition USA, Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0547-2023 | Class III | Avicel DG, MCC/Dibasic Calcium Phosphate, Net C... | Apr 13, 2023 |
| D-0545-2023 | Class III | Avicel PH-102 NF, Microcrystalline Cellulose NF... | Apr 13, 2023 |
| D-0544-2023 | Class III | Avicel PH-101 NF, Microcrystalline Cellulose NF... | Apr 13, 2023 |
| D-0352-2023 | Class III | BD-102 NF, Microcrystalline Cellulose, NF, Ph. ... | Feb 1, 2023 |
| D-0350-2023 | Class III | Avicel PH- 102 NF, Microcrystalline Cellulose, ... | Feb 1, 2023 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.